Antidepressant Maker Seaport Raises $255 Million in Upsized IPO

Seaport Therapeutics Inc., a clinical-stage biotechnology company focused on antidepressants and anxiety drugs, raised nearly $255 million in an upsized US initial public offering that priced at the top of its marketed range.

The neuro-psychiatry company sold 14.16 million shares at $18 each, according to a statement Thursday confirming an earlier Bloomberg News report. The biotech firm had offered 11.8 million shares for $16 to $18 each, its filings show.